WallStSmart

Niagen Bioscience, Inc. (NAGE)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Niagen Bioscience, Inc. generates 17476% more annual revenue ($130.42M vs $742,000). NAGE leads profitability with a 14.3% profit margin vs 0.0%. NAGE earns a higher WallStSmart Score of 45/100 (D+).

NAGE

Hold

45

out of 100

Grade: D+

Growth: 7.3Profit: 6.5Value: 6.0Quality: 8.0
Piotroski: 4/9Altman Z: 1.90

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NAGE3 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Return on EquityProfitability
22.6%9/10

Every $100 of equity generates 23 in profit

P/E RatioValuation
17.2x8/10

Attractively priced relative to earnings

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

NAGE4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.3%4/10

3.3% revenue growth

Altman Z-ScoreHealth
1.904/10

Grey zone — moderate risk

Market CapQuality
$287.52M3/10

Smaller company, higher risk/reward

Free Cash FlowQuality
$-1.25M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NAGE

The strongest argument for NAGE centers on Debt/Equity, Return on Equity, P/E Ratio.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : NAGE

The primary concerns for NAGE are Revenue Growth, Altman Z-Score, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

NAGE carries more volatility with a beta of 2.17 — expect wider price swings.

NAGE is growing revenue faster at 3.3% — sustainability is the question.

NAGE generates stronger free cash flow (-1M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NAGE scores higher overall (45/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Niagen Bioscience, Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Niagen Bioscience, Inc. is a bioscience company engages in developing healthy aging products. The company is headquartered in Los Angeles, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?